In clinical trials
Immune & defense
LL-37
Evidence
Early clinical trials
Class
Human cathelicidin antimicrobial peptide
KEY TAKEAWAY
LL-37 is the only cathelicidin antimicrobial peptide made by human cells. It kills microbes and shapes immune responses. A small phase 2 trial tested it on hard-to-heal leg ulcers.
Written by the Veylo editorial team · Updated
November 2026
What it is
The body's own antimicrobial defense peptide
Studied for
Chronic wound healing and infection
Key fact
A small randomized trial in venous leg ulcers reported improved healing
Route
Topical (investigational)
Evidence strength
Early clinical trials
LL-37 is a 37-amino-acid peptide released from a larger protein when immune cells and skin cells detect infection.
It disrupts microbial membranes and signals immune cells. It also influences cell migration and blood vessel growth during wound repair.
LL-37 is not approved by the FDA. It remains investigational.
Studied for wounds, skin infections and as a model for new antimicrobial drugs.
Topical use was well tolerated in a small trial. High levels have been linked to inflammation in some skin conditions, so more safety work is needed.
Grönberg A et al. Treatment with LL-37 is safe and effective in enhancing healing of hard-to-heal venous leg ulcers. Wound Repair Regen. 2014;22:613-621.
Veylo content is educational and not medical advice. Peptides that are not FDA-approved are not approved for the uses described.